Goldan Keith A.
SEC CIK 1495411 · EDGAR
BoughtSold
Most active insiders at SNDX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Metzger Michael A | CEO, Dir | — | $1.43M |
| 2 | Botwood Nicholas A.J. | CMO, Head of R, D | — | $1.18M |
| 3 | Goldan Keith A. | CFO | — | $137.0K |
| 4 | Rizo Aleksandra | Dir | — | — |
| 5 | Jarrett Jennifer | Dir | — | — |
| 6 | Huber Martin H. Jr. | Dir | — | — |
| 7 | Legault Pierre | Dir | — | — |
| 8 | Katkin Keith | Dir | — | — |
| 9 | Podlesak Dennis | Dir | — | — |
Transactions 17
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-02 16:30 | 2026-06-01 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | S - Sale | $18.99 | -1,177 | 139.3K | -0.8% | -$22.4K | |
| 2026-04-07 08:47 | 2026-04-01 | ABEO | ABEONA THERAPEUTICS INC. | Goldan Keith A. | Dir | A - Grant | $0.00 | +32.8K | 32.8K | New | $0 | |
| 2026-02-10 | 2026-02-09 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | S - Sale | $21.03 | -3,410 | 140.4K | -2% | -$71.7K | |
| D | 2026-02-06 | 2026-01-30 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | J - Other | $8.48 | +1,219 | 93.7K | +1% | +$10.3K |
| D | 2026-02-06 | 2026-02-06 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | S - Sale | $20.62 | -2,082 | 143.8K | -1% | -$42.9K |
| DM | 2026-02-06 | 2026-02-04 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | A - Grant | $0.00 | +52.2K | 115.2K | +83% | $0 |
| 2025-12-01 | 2025-12-01 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | G - Gift | $0.00 | -1,224 | 92.5K | -1% | $0 | |
| 2025-08-07 | 2025-07-31 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | J - Other | $8.43 | +1,226 | 93.7K | +1% | +$10.3K | |
| 2025-07-18 | 2025-07-16 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | S - Sale | $9.29 | -1,296 | 92.5K | -1% | -$12.0K | |
| 2025-05-19 | 2025-05-19 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | P - Purchase | — | +3,000 | 93.7K | +3% | — | |
| 2025-02-12 | 2025-02-10 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | S - Sale | $15.50 | -3,777 | 90.7K | -4% | -$58.5K | |
| DM | 2025-02-07 | 2025-02-05 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | A - Grant | $0.00 | +41.9K | 94.5K | +80% | $0 |
| 2024-06-17 | 2024-06-14 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | P - Purchase | $20.03 | +1,250 | 52.6K | +2% | +$25.0K | |
| DM | 2024-02-09 | 2024-02-07 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | A - Grant | $0.00 | +46.7K | 39.7K | New | $0 |
| DM | 2024-02-09 | 2023-07-31+ | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | J - Other | $17.72 | +2,045 | 3,490 | +142% | +$36.2K |
| 2023-06-14 | 2023-06-13 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | S - Sale | $22.31 | -577 | 2,628 | -18% | -$12.9K | |
| D | 2022-06-15 | 2022-06-13 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | A - Grant | $0.00 | +3,205 | 3,205 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations